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Summary  The  adenosine  nucleoside  analog  BCX4430  is  a  direct-acting  antiviral
drug  under  investigation  for  the  treatment  of  serious  and  life-threatening  infec-
tions  from  highly  pathogenic  viruses,  such  as  the  Ebola  virus.  Cellular  kinases
phosphorylate  BCX4430  to  a  triphosphate  that  mimics  ATP;  viral  RNA  polymerasesMarburg  virus  disease;
MERS-CoV;
Yellow  Fever
incorporate  the  drug’s  monophosphate  nucleotide  into  the  growing  RNA  chain,  caus-
ing  premature  chain  termination.  BCX4430  is  active  in  vitro  against  many  RNA  viral
pathogens,  including  the  ﬁloviruses  and  emerging  infectious  agents  such  as  MERS-
CoV  and  SARS-CoV.  In  vivo,  BCX4430  is  active  after  intramuscular,  intraperitoneal,
and  oral  administration  in  a  variety  of  experimental  infections.  In  nonclinical  studies
involving  lethal  infections  with  Ebola  virus,  Marburg  virus,  Rift  Valley  fever  virus,  and
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Development  of  broad-spectrum  antiviral  BCX4430  for  E
Yellow  Fever  virus,  BCX4430
conducted  in  several  models
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ackground
ucleoside  analog  drugs  have  been  highly  suc-
essful  in  the  treatment  of  a  range  of  serious  or
ife-threatening  viral  infections.  Nucleoside  analogs
arget fundamental  reproductive  mechanisms  of
he viral  genome.  For  example,  acyclovir,  which
as introduced  in  the  1980s  to  treat  herpesvirus
ncephalitis  [1,2],  targets  DNA  polymerase;  zidovu-
ine, which  was  introduced  in  the  1990s  to  treat
nfections  of  human  immunodeﬁciency  virus  [3],
argets reverse  transcriptase;  and  sofosbuvir,  which
as recently  approved  for  the  treatment  of  hepati-
is C,  targets  RNA  polymerase  [4].
A viral-encoded  RNA  polymerase  is  essential  for
eplication  of  RNA  viruses  in  host  cells  and  catalyzes
he synthesis  of  multiple  copies  of  complementary
NA from  the  template  viral  RNA.  Each  base-paired
ucleotide is  incorporated  through  speciﬁc  bind-
ng of  the  triphosphate  nucleotide  to  the  enzyme
nd the  RNA  template,  followed  by  cleavage  of
he pyrophosphate  and  covalent  bonding  of  the  5′-
onophosphate  nucleotide  to  the  3′ position  in  the
rowing RNA  strand.  Therefore,  desirable  charac-
eristics for  antiviral  nucleosides  include  efﬁcient
ptake into  cells  and  efﬁcient  conversion  of  the
ucleoside to  the  triphosphate  nucleotide  by  mam-
alian kinases.
In fresh  hepatocytes  from  mice,  rats,  non-human
rimates and  humans  in  vitro  (Fig.  1,  left  panel)  and
fter an  IM  injection  in  rats  in  vivo  (Fig.  1, right
anel), BCX4430  is  efﬁciently  taken  up  into  cells
nd converted  to  BCX4430  triphosphate  (TP)  [5].
n vivo  conversion  of  BCX4430  to  its  TP  nucleotide
s particularly  efﬁcient;  for  example,  the  intracellu-
ar BCX4430-TP  levels  are  higher  than  plasma  levels
f the  parent  compound  within  30  min  of  intramus-
ular administration  and  continue  to  exceed  the
lasma drug  levels  by  10-  to  100-fold  for  at least
4 h after  a  single  dose.
As the  molecular  goal  of  antiviral  therapy  withNA polymerase  inhibitors  is  to  interrupt  viral
NA synthesis,  a  further  desirable  characteris-
ic of  a  candidate  nucleoside  drug  is  structural
imicry of  the  corresponding  natural  nucleotide.
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 has  demonstrated  pronounced  efﬁcacy.  In  experiments
,  both  a  reduction  in  the  viral  load  and  an  improvement
 related  to  the  dose  of  BCX4430.  A  Phase  1  clinical  trial
ion  of  BCX4430  in  healthy  subjects  is  currently  ongoing.
ziz  University  for  Health  Sciences.  All  rights  reserved.
his  mimicry  allows  the  drug  nucleotide  triphos-
hate to  be  recognized  by  the  viral  RNA  polymerase
nd to  be  substituted  for  the  corresponding  natural
ucleotide.  Artiﬁcial  nucleotides  that  are  similar  to
ither a  natural  purine  (adenosine  and  guanosine)
r a  natural  pyrimidine  (uracil  or  cytosine)  nucleo-
ide may  have  structural  modiﬁcations  to  either
he base  or  ribose  sugar  moieties  or  both.  BCX4430
Fig.  2)  is  an  adenosine  analog,  with  substitution  of
arbon for  nitrogen  at  position  7  on  the  base  and
itrogen  for  oxygen  at  position  1 on  the  ribose  ring.
Steric and  electrostatic  interactions  and
ubstitutions on  the  ribose  ring  are  known  to
lter the  conformation  of  the  sugar.  These  con-
ormational  changes  can  in  turn  affect  nucleotide
ncorporation and  chain  extension  by  polymerases.
 structural  change  from  a furanose  in  adenosine
o an  azasugar  ring  in  BCX4430  alters  the  elec-
rostatic interaction  of  the  ring,  and  the  viral
NA-dependent RNA  polymerase  is  unable  to  add
ore than  one  or  two  further  nucleotides,  as
emonstrated in  vitro  using  a hepatitis  C  RNA
olymerase  assay  (Fig.  3) [5].
In studies  of 3H-BCX4430  and 3H-adenosine,  the
uH-7 human  hepatocellular  carcinoma  cell  line
as incapable  of  incorporating  labeled  BCX4430
nto either  RNA  or  DNA,  despite  avid  incorpora-
ion of  the  labeled  natural  nucleoside  [5]. The
peciﬁcity of  BCX4430  inhibitory  activity,  and  likely
hat of  other  antiviral  nucleoside  drugs,  for  the
iral RNA  polymerase  compared  to  the  mammalian
NA and  DNA  polymerases  is  possibly  due  to  the
uperior  error—correction  capabilities  of  the  mam-
alian enzymes;  however,  other  factors  cannot  be
xcluded.
ntiviral effect of BCX4430 in cell
ulture
irus  proliferation  in  cell  culture  is  inhibited  by
ncubation  with  BCX4430.  BCX4430  displays  a  broad
pectrum  of  activity  against  a  wide  variety  of  RNA
iral pathogens.  Many  of these  viruses,  includ-
ng MERS-CoV,  EBOV,  MARV,  and  YFV,  cause  serious
222  R.  Taylor  et  al.
Figure  1  Anabolism  of  BCX4430  to  BCX4430-TP  (BCX6870)  in  hepatocytes  in  vitro  (left  panel)  and  levels  of  BCX4430  in
the  plasma  and  BCX4430-TP  in  the  liver  of  rats  after  an  IM  injection  of  BCX4430  (right  panel).  Redrawn  from  [5].  Cells
were  incubated  with  10  M  BCX4430  for  the  indicated  times,  and  the  levels  of  BCX4430-TP  were  quantitated  by  HPLC;
the  plasma  samples  were  obtained  and  the  livers  were  harvested  from  rats  following  administration  of  a  30  mg/kg
BCX4430  dose  by  intramuscular  injection,  and  the  plasma  BCX4430  and  the  liver  BCX4430-TP  were  quantitated  by
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or  fatal  infections  and  currently  have  either  no
approved  treatments  or  treatments  with  limited
efﬁcacy.  The  antiviral  activity  of  BCX4430  has  been
demonstrated  for  viruses  from  diverse  taxa,  includ-
ing positive-sense  Flaviviridae  and  Coronaviridae
RNA viruses  and  negative-sense  Filoviridae, Are-
naviridae,  Bunyaviridae,  Orthomyxoviridae,  Picor-
naviridae,  and  Paramyxoviridae  RNA  viruses  [5].
The antiviral  activity  of  BCX4430  against  the
ﬁloviruses has  also  been  evaluated  in  HeLa  cell  line
assays by  quantitation  of  intracellular  viral  RNA  for
MARV and  EBOV  and  extracellular  RNA  for  EBOV  in
the supernatant  [5].
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Figure  2  Structure  of  BCX4430  (left  panel),  an  adenosine  n
active  nucleotide  form,  BCX4430-triphosphate  (also  designateAs  reported  in  vitro,  the  EC50 values  for  BCX4430
ary across  a wide  range  from  ∼3  to  ∼68  M
5]; however,  many  cell  lines  used  for  antiviral
rug sensitivity  assays  are  inefﬁcient  at  anabolizing
CX4430  to  BCX4430-TP  (Fig.  4).  Examples  of  results
f susceptibility  assays  with  a  very  inefﬁcient  cell
ine, Vero,  and  the  Jordan  strain  of  MERS-CoV  and
7D strain  of  the  Yellow  Fever  virus  are  shown
n Fig.  5; the  EC50 estimates  are  in  the  double-
igit micromolar  range.  Apparently,  the  observed
igh EC50 values  for  BCX4430  may  be  misleading,
nd in  vivo  studies  are  required  to  investigate  the
ntiviral activity  of  this  compound.
ucleoside  analog  broad-spectrum  antiviral  drug,  and  its
d  as  BCX6870)  (right  panel).
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Figure  3  Non-obligate  chain  termination  of  hepatitis  C
through  RNA-dependent,  template-directed  RNA  synthe-
sis  by  incubation  with  BCX4430  triphosphate  (BCX6870)
in  vitro.  Chain  termination  as  a  result  of  incorporation  of
BCX4430  is  shown  in  lanes  5  and  8.  Lanes  4  and  7  show
3′-deoxyATP,  a  known  obligate  chain  terminator  positive
control.  Lane  6  shows  the  pattern  of  RNA  oligomers  made
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Figure  4  Variation  in  and  low  efﬁciency  of  conversion
of  BCX4430  to  BCX4430-TP  in  cell  lines  commonly  used
for  in  vitro  evaluation  of  antiviral  activity  of  test  agents;
the  data  shown  indicate  mean  and  SD.  Redrawn  from
[5];  right-hand  scale  indicates  the  percent  of  BCX4430-TP
mean  levels  observed  at  24  h  in  fresh  human  hepatocytes.
The  cell  lines  were  incubated  with  10  M  BCX4430  for
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was signiﬁcantly  prolonged  compared  to  that  of
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Rith  no  inhibitors  present  or  normal  nucleotides  present.
eproduced  from  [5].
fﬁcacy of BCX4430 in nonclinical virus
isease models
xperimental  disease  models  of  lethal  virus  infec-
ions in  rodents  or  non-human  primates  are  helpful
or understanding  the  potential  utility  of  candidate
ntiviral drugs.  To  date,  BCX4430  has  shown  efﬁcacy
n a  lethal  rodent  and  an  NHP  model  of  ﬁloviral  dis-
ases (Marburg  virus  disease  [MVD]  and  Ebola  virus
isease  [EVD])  [5],  as  well  as  in  rodent  models  of
ellow  Fever  [6]  and  Rift  Valley  fever  [5].
In a  study  in  cynomolgus  macaques  infected
ith MARV  [5],  0/6  controls  survived  compared  to
7/18 animals  treated  with  a  15  mg/kg  BD  dose  of
t
t
w
igure  5  Concentration—response  results  for  the  inhibition  o
ell  line  infected  with  MERS-CoV  (Jordan  N3  strain)  (left  pa
anel).
edrawn  from  [5].he  indicated  times,  and  the  levels  of  BCX4430-TP  were
uantitated  by  HPLC.
CX4430  by  IM  injection  (p  <  0.0001),  with  the  start
f treatment  delayed  up  to  48  h  post  inoculation.
he maximum  viral  load,  as  measured  by  quantita-
ion of viral  RNA  copies  in  the  peripheral  blood,  was
educed by  ∼600-fold  (geometric  mean  0.008  ×  109
ompared  to  4.79  ×  109 copies/mL,  p  <  0.0005).
ther disease  markers,  such  as  elevated  bilirubin
nd AST  from  hepatitis  and  prolonged  aPTT  and  PT
rom coagulopathy,  were  also  markedly  improved
y BCX4430  (p  <  0.005).
A dose-range  study  of  BCX4430  in  a cynomol-
us macaque  EVD  model  evaluated  doses  ranging
rom  3.4  to  16  mg/kg  BID  IM  starting  48  h  after
noculation. No  animals  survived;  however,  in  the
6 mg/kg  BID  dose  group,  the  mean  time  to  deathhe control  group  (13.2  vs.  7.2days,  p  =  0.005),  and
he geometric  mean  viral  RNA  copies/mL  in  serum
as signiﬁcantly  reduced  on  day  7  (0.049  ×  109 vs.
f  virus  proliferation  in  cell  culture  assays  using  a Vero-E6
nel)  and  the  Yellow  Fever  Virus  (YFV,  17D  strain)  (right
224  R.  Taylor  et  al.
Figure  6  Relationship  between  the  dose  of  BCX4430  to  the  antiviral  effect  (left  panel)  and  survival  (right  panel)  in
Syrian  golden  hamsters  inoculated  with  the  Yellow  Fever  virus.  The  left  panel  open  symbols  shows  data  for  each  animal
(n  =  10  per  dose  group),  and  the  horizontal  bars  shows  the  geometric  mean  for  each  dose  group;  the  inset  shows  the
best-ﬁt  nonlinear  regression  of  BCX4430  dose  with  viral  load  (GraphPad  Prism  v6.07),  indicating  a  typical  and  steep
concentration—inhibition  relationship.  The  right  panel  closed  symbols  show  the  proportion  of  animals  surviving  at  each
dose  level  in  the  same  experiment,  with  error  bars  indicating  the  exact  binomial  conﬁdence  intervals.  The  line  shows
the  best-ﬁt  logistic  regression  of  dose  with  proportion  surviving  (XLSTAT  Version  2015.5.01.23039).
Data  from  [6].
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d1.8  ×  109 copies/mL  for  controls,  a  difference  of  1.6
logs, p  =  0.028).
In  a  subsequent  study  of  BCX4430  in  a rhesus
macaque EVD  model,  all  six  animals  administered
a dose  of  25  mg/kg  IM  BID  of  BCX4430  starting
30—60 min  after  inoculation  survived  compared  to
zero of  six  controls  (p  < 0.001).  The  viral  load  was
reduced  by  2.9  logs  for  this  group  on  day  6,  and  the
geometric  mean  viral  RNA  copies/mL  in  serum  was
0.035 ×  108 vs.  3.1  ×  108 for  controls  (p  =  0.004).
BCX4430  showed  potent  in  vivo  antiviral  activ-
ity in  studies  using  a  Yellow  Fever  model  in  Syrian
golden hamsters  [6]. The  administration  of  BCX4430
at a  dose  of  12  mg/kg  QD  was  highly  effective
in reducing  mortality  even  when  the  initiation
of treatment  was  delayed  by  as  much  as  4  days
after inoculation.  It  is  important  to  note  that  the
in vitro  susceptibility  testing  for  YFV  has  shown  a
double-digit  micromolar  EC50 (Fig.  5,  right  panel),
emphasizing that  it  would  be  unwise  to  reject  the
utility of  BCX4430  for  a  particular  virus  based  solely
on in  vitro  susceptibility  testing.The slope  of  the  relationship  of  the  dose  of
BCX4430 to  both  antiviral  effect  and  survival  in  non-
clinical models  of  lethal  viral  infections  is  steep.  An
example is  shown  for  experimental  Yellow  Fever  in
B
e
s
oamsters  in  Fig.  6. The  estimated  Hill  slope  for  the
og antiviral  effect  was  2.3,  and  the  ED50 dose  was
stimated  to  be  6.3  mg/kg  BID  (r  =  0.75)  (Fig.  6,  left
anel). The  ED50 dose  for  survival  was  estimated
o be  2.75  mg/kg  BID,  and  in  the  logistic  regres-
ion best  ﬁt  for  the  experimental  data  (p  <  0.001,
 =  0.86),  doubling  the  dose  from  ∼3  mg/kg  BID
o 6  mg/kg  BID  increased  the  odds  of  survival  by
pproximately  5-fold.  The  dose—response  for  sur-
ival was  also  very  steep  in  a mouse  model  of
arburg virus  disease  [5].
linical studies with BCX4430
 Phase  1 ﬁrst-in-human  study  of  intramuscular
njection of  BCX4430  (NCT02319772)  in  healthy
ubjects is  ongoing;  for  single  doses  of  0.3
o10.0 mg/kg,  plasma  exposure  to  BCX4430  was
ose-related  and  linear.  The  ﬁrst  multi-day  cohort
as evaluated  at  a dose  of  2.5  mg/kg  QD  for  7
ays, and  the  dose  escalation  is  continuing.  To  date,
CX4430  injections  have  been  safe  and  well  tol-
rated.  Additional  studies  of  BCX4430  in  healthy
ubjects  are  planned  using  the  intravenous  route
f administration.
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Nevelopment  of  broad-spectrum  antiviral  BCX4430  
ntegrated assessment of BCX4430 as a
andidate antiviral drug for highly
athogenic emerging and neglected
nfectious diseases
he  mechanism  of  action,  in  vitro  antiviral  activity,
nd nonclinical  efﬁcacy  of  BCX4430  discussed  above
epresent  a  highly  attractive  proﬁle  for  a  broad-
pectrum antiviral  agent.  The  body  of  evidence
or BCX4430  has  attracted  funding  for  continued
evelopment from  US  Government  agencies;  this
rogram is now  supported  in  part  with  US  Fed-
ral contracts  from  NIH/NIAID1 and  HHS/BARDA.2
he  BCX4430  program  has  now  advanced  into  early
linical  development,  together  with  late-stage
onclinical toxicology  and  drug  supply  scale-up
ctivities.
The BCX4430  drug  substance  is  a  crystalline
olid that  has  proven  to  be  stable  in  ongoing  stud-
es for  at  least  2  years.  As  a  traditional  small
olecule chemical  entity,  development  of  both  the
CX4430 drug  substance  synthetic  processes  and
he formulated  drug  product  can  be  pursued  using
tandard  chemistry,  manufacturing,  and  formula-
ion research  practices,  with  the  expectation  that
arge-scale  synthesis  of  a  high-quality  ﬁnished  prod-
ct can  be  achieved.  The  pharmacokinetic  proﬁle
f BCX4430  in  non-clinical  species  [5]  supports  the
valuation  of  daily  dosing,  and  its  efﬁcacy  has  been
emonstrated  in  experimental  viral  infection  mod-
ls by  both  parenteral  (IM  and  IP)  and  oral  routes
5,6].  BCX4430  administration  has  been  generally
afe and  well  tolerated  in  an  ongoing  healthy  human
ubjects  safety  study.  The  clinical  pharmacology
roﬁle that  emerges  from  these  studies  will  help  to
eﬁne and  optimize  therapeutic  dosing  schedules  to
omplete the  development  of  BCX4430  under  the
nimal  Rule  [7]  and  for  use  in  clinical  testing  in
elevant  disease  settings.
ecommendations for future research
ith  BCX4430
he  recent  disastrous  outbreak  of  Ebola  virus  dis-
ase in  West  African  nations  and  the  emergence
f MERS-CoV  infection  in  the  Middle  East  under-
core the  importance  and  urgency  of  successful
evelopment  of  effective  and  safe  antiviral  drugs
or treatment  of  these  life-threatening  illnesses.
n addition  to  continued  drug  synthesis  and  formu-
ation  research  to  enable  large-scale  drug  supply
1 Contract #HHSN272201300017C.
2 Contract #HHSO100201500007C.
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nd  inventory,  the  most  important  categories  of
esearch to  complete  for  BCX4430  in  the  near  term
re in  the  ﬁelds  of  nonclinical  pharmacology,  non-
linical disease  models,  and  clinical  pharmacology:
 Dose—response  studies  in  nonclinical  infection
models.
 Nonclinical  pharmacology  studies  of  plasma  and
tissue pharmacokinetics  in  healthy  and  experi-
mentally infected  animals.
 Optimized  dose-schedule  studies  in  nonclinical
disease models.
 Delayed  dosing  studies  in  nonclinical  disease
models.
 Completion  of  Phase  1  studies  in  healthy  sub-
jects to  deﬁne  the  maximum  tolerated  dose,  and
explore exposure  via  IM  and  IV  routes  of  admin-
istration.
 Completion  of  nonclinical  safety  studies  to  sup-
port emergency  usage  readiness  evaluation.
 Evaluation  of  the  relationship  of  both  dose  and
plasma  drug  exposure  to  virologic  response  in
patients  with  relevant  viral  infections  where
there is  an  opportunity  to  do  so.
Evidence from  this  research  program  would
rovide a  sound  basis  for  the  selection  of  BCX4430
oses and  regimens  for  use  in  an emergency
esponse  setting.
unding
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